Su Chang, Hoffman Katherine L, Xu Zhenxing, Sanchez Elizabeth, Siempos Ilias I, Harrington John S, Racanelli Alexandra C, Plataki Maria, Wang Fei, Schenck Edward J
Department of Health Service Administration and Policy, College of Public Health, Temple University, Philadelphia, PA.
Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Crit Care Explor. 2021 Dec 2;3(12):e0589. doi: 10.1097/CCE.0000000000000589. eCollection 2021 Dec.
This report aims to characterize the kinetics of serum albumin in critically ill patients with coronavirus disease 2019 compared with critically ill patients with sepsis-induced acute respiratory distress syndrome.
Retrospective analysis.
We analyzed two critically ill cohorts, one with coronavirus disease 2019 and another with sepsis-induced acute respiratory distress syndrome, treated in the New York Presbyterian Hospital-Weill Cornell Medical Center.
Adult patients in the coronavirus disease 2019 cohort, diagnosed through reverse transcriptase-polymerase chain reaction assays performed on nasopharyngeal swabs, were admitted from March 3, 2020, to July 10, 2020. Adult patients in the sepsis-induced acute respiratory distress syndrome cohort, defined by Sepsis III criteria receipt of invasive mechanical ventilation and a Pao/Fio ratio less than 300 were admitted from December 12, 2006, to February 26, 2019.
None.
We evaluated serial serum albumin levels within 30 days after ICU admission in each cohort. We then examined the albumin progression trajectories, aligned at ICU admission time to test the relationship at a similar point in disease progression, in survivors and nonsurvivors. Albumin trajectory in all critically ill coronavirus disease 2019 patients show two distinct phases: phase I (deterioration) showing rapid albumin loss and phase II (recovery) showing albumin stabilization or improvement. Meanwhile, albumin recovery predicted clinical improvement in critical coronavirus disease 2019. In addition, we found a deterioration and recovery trends in survivors in the sepsis-induced acute respiratory distress syndrome cohort but did not find such two-phase trend in nonsurvivors.
The changes in albumin associated with coronavirus disease 2019 associated respiratory failure are transient compared with sepsis-associated acute respiratory distress syndrome and highlight the potential for recovery following a protracted course of severe coronavirus disease 2019.
本报告旨在描述2019冠状病毒病重症患者血清白蛋白的动力学特征,并与脓毒症诱导的急性呼吸窘迫综合征重症患者进行比较。
回顾性分析。
我们分析了纽约长老会医院-威尔康奈尔医学中心治疗的两个重症队列,一个是2019冠状病毒病患者队列,另一个是脓毒症诱导的急性呼吸窘迫综合征患者队列。
2019冠状病毒病队列中的成年患者通过对鼻咽拭子进行逆转录聚合酶链反应检测确诊,于2020年3月3日至2020年7月10日入院。脓毒症诱导的急性呼吸窘迫综合征队列中的成年患者根据脓毒症3.0标准定义,即接受有创机械通气且氧合指数小于300,于2006年12月12日至2019年2月26日入院。
无。
我们评估了每个队列入住重症监护病房(ICU)后30天内的系列血清白蛋白水平。然后我们检查了白蛋白的变化轨迹,在ICU入院时间对齐,以测试疾病进展相似点上幸存者和非幸存者之间的关系。所有2019冠状病毒病重症患者的白蛋白轨迹显示出两个不同阶段:第一阶段(恶化)显示白蛋白快速丢失,第二阶段(恢复)显示白蛋白稳定或改善。同时,白蛋白恢复预示着重症2019冠状病毒病患者临床状况改善。此外,我们在脓毒症诱导的急性呼吸窘迫综合征队列的幸存者中发现了恶化和恢复趋势,但在非幸存者中未发现这种两阶段趋势。
与脓毒症相关的急性呼吸窘迫综合征相比,2019冠状病毒病相关呼吸衰竭中白蛋白的变化是短暂的,这突出了重症2019冠状病毒病长期病程后恢复的潜力。